Edition:
United States

Amarantus Bioscience Holdings Inc (AMBS.PK)

AMBS.PK on OTC Markets Group

0.04USD
26 May 2017
Change (% chg)

$0.00 (+1.98%)
Prev Close
$0.04
Open
$0.04
Day's High
$0.04
Day's Low
$0.04
Volume
10,408
Avg. Vol
398,563
52-wk High
$0.09
52-wk Low
$0.01

Latest Key Developments (Source: Significant Developments)

Amarantus Bioscience received orphan drug designation from the US FDA
Wednesday, 10 Feb 2016 07:45am EST 

Amarantus Biosciences Holdings inc:Says it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).Published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain.  Full Article

Amarantus BioScience Holdings, Inc submits Orphan Drug Designation Application to FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia
Thursday, 22 Oct 2015 09:15am EDT 

Amarantus BioScience Holdings, Inc:Says has submitted a request to the US FDA for orphan drug designation (ODD) for eltoprazine in the treatment of levodopa-induced dyskinesia (PD-LID).  Full Article

Amarantus closes $5.5 million capital infusion through issuance of preferred stock and secured debt convertible
Thursday, 1 Oct 2015 07:32am EDT 

Amarantus BioScience Holdings, Inc:Completed issuance of $2.75 million of newly designated Series H convertible preferred stock in a registered direct offering.Issues $2.75 million in secured debt in a private placement for a total of $5.5 million to a single institutional investor.  Full Article

Amarantus BioScience Holdings Inc receives orphan drug designation from the U.S. Food and Drug Administration for MANF for the treatment of retinal artery occlusion
Monday, 14 Sep 2015 10:30am EDT 

Amarantus BioScience Holdings Inc:Says U.S. Food and Drug Administration has granted company's investigational drug mesencephalic-astrocyte-derived neurotrophic factor orphan drug designation for the treatment of retinal artery occlusion.Retinal artery occlusion is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.  Full Article

Amarantus Bioscience Holdings Inc announces acquisition of Cutanogen Corporation - From 8k
Wednesday, 15 Jul 2015 07:00am EDT 

Amarantus Bioscience Holdings Inc:Says exercised its previously disclosed option to acquire Cutanogen Corporation.Says pursuant to a Share Purchase Agreement among the Company and Lonza Walkersville, Inc. dated July 14, the Company paid $4,000,000 to Lonza upon closing.  Full Article

More From Around the Web